← board
KPHMW
distress 3/10 · well-funded / low riskRevenue
pre-revenue
Liquidity
$14M
Runway
1.3 yrs
Shares 1y
+29%
Overview
- Total Shares
- 4.43M
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2025-05-30partnershipKIO-301 · Exclusive option agreement with Senju for development and commercialization in Asia.SEC 8-K
- 2024-10-29fda agreementKIO-301 · FDA approval to initiate ABACUS-2 Phase 2 trial for retinitis pigmentosa.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 4,431,940 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.